Published in J Clin Invest on May 01, 2008
Targeting of drugs and nanoparticles to tumors. J Cell Biol (2010) 4.07
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02
Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A (2012) 1.30
Combinatorial peptide libraries: mining for cell-binding peptides. Chem Rev (2013) 1.07
Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials (2011) 1.02
T-cell-independent antitumor effects of CD40 ligation. Int Rev Immunol (2012) 0.99
Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget (2015) 0.89
The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment. J Immunol Res (2014) 0.88
The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Rev Clin Pharmacol (2011) 0.88
Remodeling of tumor stroma and response to therapy. Cancers (Basel) (2012) 0.87
Revisiting the role of T cells in tumor regression. Oncoimmunology (2012) 0.81
Rapid copper acquisition by developing murine mesothelioma: decreasing bioavailable copper slows tumor growth, normalizes vessels and promotes T cell infiltration. PLoS One (2013) 0.81
Turning the tumor microenvironment into a self vaccine site. Oncoimmunology (2012) 0.78
Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors. Cancer Immunol Immunother (2014) 0.76
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther (2017) 0.76
CD40 therapy and surgery: a potential immunologic partnership. J Immunother (2013) 0.75
De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat Immunol (2017) 0.75
Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol (1985) 25.52
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70
Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature (1998) 11.08
Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature (1985) 9.78
Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med (1996) 9.31
Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol (2005) 5.80
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature (1998) 5.21
The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity (1996) 4.02
Genes that distinguish physiological and pathological angiogenesis. Cancer Cell (2007) 3.35
Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med (1999) 3.29
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92
CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med (1999) 2.77
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med (1999) 2.61
Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2003) 2.56
Tumour vascular targeting. Nat Rev Cancer (2005) 2.56
Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res (2002) 2.35
IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med (2007) 2.23
Expression of functional CD40 by vascular endothelial cells. J Exp Med (1995) 2.16
Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell (2003) 2.07
CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc Natl Acad Sci U S A (1994) 1.96
Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood (2004) 1.77
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood (2002) 1.66
IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol (2003) 1.62
Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol (2003) 1.53
Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation. J Leukoc Biol (1995) 1.53
Limited capacity for tolerization of CD4+ T cells specific for a pancreatic beta cell neo-antigen. Immunity (1995) 1.52
Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med (2002) 1.48
Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. J Exp Med (1995) 1.37
CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A (2002) 1.34
Transformation of the microvascular system during multistage tumorigenesis. Int J Cancer (2002) 1.30
Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther (2004) 1.29
Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci U S A (1999) 1.29
CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol (2004) 1.26
Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med (2001) 1.22
Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med (2006) 1.15
Mini-review: overcoming tumor-intrinsic resistance to immune effector function. Eur J Immunol (2004) 1.14
CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J Immunol (1997) 1.08
Determinants of the B-cell response against a transgenic autoantigen. Proc Natl Acad Sci U S A (1990) 1.07
T-cell responsiveness to an oncogenic peripheral protein and spontaneous autoimmunity in transgenic mice. Proc Natl Acad Sci U S A (1992) 1.05
CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets. Cell Immunol (1999) 1.02
Tumor growth or regression: powered by inflammation. J Leukoc Biol (2006) 0.96
CD40-induced countercurrent conduits for tumor escape or elimination? Trends Immunol (2007) 0.95
Pathogenic role of B cells in anti-CD40-induced necroinflammatory liver disease. Am J Pathol (2006) 0.94
CD40 ligation for immunotherapy of solid tumours. J Immunol Methods (2001) 0.90
Anti-CD40 conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors. J Immunol (2007) 0.88
Expression of porcine interleukin-2 in Escherichia coli. J Vet Med Sci (2000) 0.77
Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects. Biol Blood Marrow Transplant (2004) 0.76
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) (2005) 4.96
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature (2008) 3.05
Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol (2005) 3.05
The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med (2003) 2.94
Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell (2013) 2.89
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell (2009) 2.73
RAGE signaling sustains inflammation and promotes tumor development. J Exp Med (2008) 2.51
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res (2002) 2.35
Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock (2009) 2.26
CD11c depletion severely disrupts Th2 induction and development in vivo. J Exp Med (2010) 2.26
Impaired assembly of the major histocompatibility complex class I peptide-loading complex in mice deficient in the oxidoreductase ERp57. Nat Immunol (2005) 2.09
Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med (2003) 2.01
Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci U S A (2005) 1.97
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest (2004) 1.92
Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood (2004) 1.77
ERp57 is essential for efficient folding of glycoproteins sharing common structural domains. EMBO J (2006) 1.73
A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells. Eur J Immunol (2008) 1.68
Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur J Immunol (2006) 1.45
Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol (2008) 1.41
Functionally relevant neutrophilia in CD11c diphtheria toxin receptor transgenic mice. Nat Methods (2012) 1.40
Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.LuciDTR mice. J Immunol (2010) 1.39
Temporal Cre-mediated recombination exclusively in endothelial cells using Tie2 regulatory elements. Genesis (2002) 1.38
Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur J Immunol (2010) 1.38
Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat Med (2011) 1.34
Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A (2012) 1.30
Transformation of the microvascular system during multistage tumorigenesis. Int J Cancer (2002) 1.30
Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol (2003) 1.30
Dendritic cells control T cell tonic signaling required for responsiveness to foreign antigen. Proc Natl Acad Sci U S A (2010) 1.27
Consequences of ERp57 deletion on oxidative folding of obligate and facultative clients of the calnexin cycle. J Biol Chem (2006) 1.27
Wnt2 acts as a cell type-specific, autocrine growth factor in rat hepatic sinusoidal endothelial cells cross-stimulating the VEGF pathway. Hepatology (2008) 1.27
Cross-presentation of oral antigens by liver sinusoidal endothelial cells leads to CD8 T cell tolerance. Eur J Immunol (2005) 1.27
CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol (2004) 1.26
Brain development in mice lacking L1-L1 homophilic adhesion. J Cell Biol (2004) 1.19
A major role for tapasin as a stabilizer of the TAP peptide transporter and consequences for MHC class I expression. Eur J Immunol (2003) 1.19
High TCR diversity ensures optimal function and homeostasis of Foxp3+ regulatory T cells. Eur J Immunol (2011) 1.19
Recruitment of MHC class I molecules by tapasin into the transporter associated with antigen processing-associated complex is essential for optimal peptide loading. J Immunol (2002) 1.18
Cutting edge: IL-7-dependent homeostatic proliferation of CD8+ T cells in neonatal mice allows the generation of long-lived natural memory T cells. J Immunol (2004) 1.18
Chronic helminth infection promotes immune regulation in vivo through dominance of CD11cloCD103- dendritic cells. J Immunol (2011) 1.16
Immune synapse formation determines interaction forces between T cells and antigen-presenting cells measured by atomic force microscopy. Proc Natl Acad Sci U S A (2009) 1.14
Mini-review: overcoming tumor-intrinsic resistance to immune effector function. Eur J Immunol (2004) 1.14
Commensal microflora and interferon-gamma promote steady-state interleukin-7 production in vivo. Eur J Immunol (2010) 1.14
Deficiency of liver sinusoidal scavenger receptors stabilin-1 and -2 in mice causes glomerulofibrotic nephropathy via impaired hepatic clearance of noxious blood factors. J Clin Invest (2011) 1.14
Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog (2011) 1.11
A non-enzymatic function of 17beta-hydroxysteroid dehydrogenase type 10 is required for mitochondrial integrity and cell survival. EMBO Mol Med (2010) 1.09
Homeostasis of dendritic cells in lymphoid organs is controlled by regulation of their precursors via a feedback loop. Blood (2009) 1.05
CD80 and CD86 differentially regulate mechanical interactions of T-cells with antigen-presenting dendritic cells and B-cells. PLoS One (2012) 1.03
Gelatinase B deficiency protects against endotoxin shock. Eur J Immunol (2002) 1.03
Boosting regulatory T cells limits neuroinflammation in permanent cortical stroke. J Neurosci (2013) 1.02
Quantitative comparison of click beetle and firefly luciferases for in vivo bioluminescence imaging. J Biomed Opt (2007) 1.02
Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res (2006) 1.01
Invading macrophages play a major role in the liver progenitor cell response to chronic liver injury. J Hepatol (2010) 1.00
TNF-induced target cell killing by CTL activated through cross-presentation. Cell Rep (2012) 0.99
IFN-gamma receptor signaling regulates memory CD8+ T cell differentiation. J Immunol (2010) 0.99
Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice. Hepatology (2013) 0.99
CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. J Immunol (2010) 0.98
CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion. Clin Exp Metastasis (2011) 0.98
Regulator of G protein signaling 5: a new player in vascular remodeling. Trends Cardiovasc Med (2009) 0.98
Depletion of dendritic cells enhances innate anti-bacterial host defense through modulation of phagocyte homeostasis. PLoS Pathog (2012) 0.98
Advanced glycation end product receptor-mediated cellular dysfunction. Ann N Y Acad Sci (2005) 0.97
Type 2 innate immunity in helminth infection is induced redundantly and acts autonomously following CD11c(+) cell depletion. Infect Immun (2012) 0.97
Control of peripheral T-lymphocyte tolerance in neonates and adults. Trends Immunol (2005) 0.96
Tumor growth or regression: powered by inflammation. J Leukoc Biol (2006) 0.96
Gelatinase B/MMP-9 as an inflammatory marker enzyme in mouse zymosan peritonitis: comparison of phase-specific and cell-specific production by mast cells, macrophages and neutrophils. Immunobiology (2007) 0.96
Nck adaptors are positive regulators of the size and sensitivity of the T-cell repertoire. Proc Natl Acad Sci U S A (2010) 0.95
Modulation of g protein signaling normalizes tumor vessels. Cancer Res (2009) 0.95
CpG-ODN-induced inflammation is sufficient to cause T-cell-mediated autoaggression against hepatocytes. Eur J Immunol (2002) 0.95
Frequent downregulation of DMBT1 and galectin-3 in epithelial skin cancer. Int J Cancer (2003) 0.95
Gelatinase B/matrix metalloproteinase-9 contributes to cellular infiltration in a murine model of zymosan peritonitis. Immunobiology (2006) 0.95
Secreted frizzled-related protein 4: an angiogenesis inhibitor. Am J Pathol (2010) 0.94
Innate immune cells contribute to the IFN-gamma-dependent regulation of antigen-specific CD8+ T cell homeostasis. J Immunol (2006) 0.93
Neutrophil elastase activity compensates for a genetic lack of matrix metalloproteinase-9 (MMP-9) in leukocyte infiltration in a model of experimental peritonitis. J Leukoc Biol (2008) 0.92
JunB is required for endothelial cell morphogenesis by regulating core-binding factor beta. J Cell Biol (2006) 0.92
A novel function of junctional adhesion molecule-C in mediating melanoma cell metastasis. Cancer Res (2011) 0.92
Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. J Immunol (2009) 0.91